Showing results (151-160 of 175) with videos related to

Sort By:
Pageof 18
Acta Pharmacologica Sinica|October 19, 2022
SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16Yuan Liu, Wei-Yao Kong, Cui-Fu Yu, et al.
British Journal of Haematology|October 23, 2025
Risk factors for DIC in paediatric APL: Insights from the CCLG-APL 2016 studyQingyuan Xu, Linya Wang, Shaoyan Hu, et al.
Frontiers in Oncology|April 11, 2022
Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic PatternYing-Zi Li, Bo Chen, Xiao-Yi Lin, et al.
European Journal of Haematology|June 7, 2024
Prognosis of pediatric BCP-ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG-2016 studyShaofen Lin, Ning Liao, Xinyu Li, et al.
JAMA Oncology|October 25, 2019
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical TrialZhimin Shao, Da Pang, Hongjian Yang, et al.
Annals of Translational Medicine|June 7, 2019
Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohortsGuochun Zhang, Yulei Wang, Bo Chen, et al.
Ebiomedicine|August 28, 2021
Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumoursBo Chen, Guochun Zhang, Jianguo Lai, et al.
Cancer Research and Treatment|May 29, 2024
Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution StudyTingting Chen, Chenggong Zeng, Juan Wang, et al.
Haematologica|February 5, 2026
Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemiaLiyan Fan, Li Gao, Weina Zhang, et al.
Nature Communications|March 9, 2024
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trialLiang Huang, Da Pang, Hongjian Yang, et al.
Pageof 18